- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06379789
Исследование, чтобы выяснить, является ли REGV131-LNP1265 безопасным и помогает ли организму вырабатывать фактор свертывания крови у детей, подростков и взрослых пациентов с гемофилией B (BEYOND-9)
Открытое исследование, состоящее из двух частей, REGV131-LNP1265, терапии инсерцией гена фактора свертывания крови IX на основе CRISPR/Cas9 у участников с гемофилией B
Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
The main aim of this study is to find a safe and well-tolerated dose of the study drug by checking the side effects that may happen from taking it, both in the near term and over time.
The study is looking at several other research questions including:
- How much study drug is in the blood at different times
- Whether the body makes antibodies against parts of the study drug, which could make the drug less effective or could lead to side effects. Antibodies are proteins produced by the body's immune system in response to a foreign substance
- Whether the body makes antibodies against the clotting factor replacement therapy
- How often factor replacement therapy is needed, both on a regular basis for prevention of bleeding, and as needed to treat bleeding events (and it if changes after taking study drug)
- Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood
Обзор исследования
Подробное описание
The study will be conducted with a 2-part adaptive design, with enrollment of patients into sequential parts of the study.
Part 1: Dose Escalation and Dose Confirmation in adult patients ≥18 years of age
- Dose Escalation Cohorts to determine the Recommended Dose for Expansion (RDE) of REGV131-LNP1265
- Dose Confirmation Cohort to gain further confidence in safety, tolerability, and Coagulation Factor IX (FIX) functional activity data at the RDE
Part 2: Dose Expansion at the RDE
- Part 2A: Adult patients ≥18 years of age: RDE of REGV131-LNP1265, as determined in Part 1
- Part 2B: Adolescent patients ≥12 to <18 years of age will be administered weight-adjusted RDE
- Part 2C: Adolescent and Pediatric patients ≥2 to <12 years may be enrolled in an age staggered sequential manner; first participants aged ≥6 to <12 years and then participants ≥2 to <6 years of age and will receive a weight-adjusted RDE
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Clinical Trials Administrator
- Номер телефона: 844-734-6643
- Электронная почта: clinicaltrials@regeneron.com
Места учебы
-
-
New South Wales
-
Camperdown, New South Wales, Австралия, 2050
- Рекрутинг
- Royal Prince Alfred Hospital, Haemophilia Treatment Centre
-
-
Queensland
-
Herston, Queensland, Австралия, 4029
- Рекрутинг
- Royal Brisbane and Women's Hospital
-
-
South Australia
-
Adelaide, South Australia, Австралия, 5000
- Рекрутинг
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Австралия, 3004
- Рекрутинг
- Alfred Hospital
-
-
-
-
-
Rio de Janeiro, Бразилия, 20211030
- Рекрутинг
- Hemorio
-
-
Espírito Santo
-
Vitória, Espírito Santo, Бразилия, 29047-105
- Рекрутинг
- Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos
-
-
São Paulo
-
Campinas, São Paulo, Бразилия, 13084-878
- Рекрутинг
- Hemocentro Unicamp
-
-
-
-
-
Hamburg, Германия, 20246
- Рекрутинг
- University Hospital Hamburg Eppendorf
-
-
Hesse
-
Frankfurt am Main, Hesse, Германия, 60590
- Рекрутинг
- University Hospital Frankfurt
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Германия, 53127
- Рекрутинг
- University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine
-
-
-
-
-
Barcelona, Испания, 08035
- Рекрутинг
- Hospital Universitario Vall d'Hebron
-
Madrid, Испания, 28046
- Рекрутинг
- Hospital Universitario La Paz
-
Valencia, Испания, 46026
- Рекрутинг
- Haemostasis and Thrombosis Unit, Hospital La Fe
-
Zaragoza, Испания, 50009
- Рекрутинг
- Hospital Universitario Miguel Servet
-
-
Andalusia
-
Seville, Andalusia, Испания, 41013
- Рекрутинг
- Hospital Universitario Virgen del Rocio
-
-
Galicia
-
A Coruña, Galicia, Испания, 15006
- Рекрутинг
- Complejo Hospitalario Universitario de A Coruña (Edificio Teresa Herrera-Materno Infantil)
-
-
Murcia
-
El Palmar, Murcia, Испания, 30120
- Рекрутинг
- Hospital Clinico Universitario Virgen De La Arrixaca
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Испания, 33011
- Рекрутинг
- Hospital Universitario Central de Asturias
-
-
-
-
-
Vicenza, Италия, 36100
- Рекрутинг
- Ospedale san Bortolo
-
-
Firenze
-
Florence, Firenze, Италия, 50134
- Рекрутинг
- Careggi University Hospital
-
-
Lombardy
-
Milan, Lombardy, Италия, 20122
- Рекрутинг
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca Granda Ospedale Maggiore Policlinico
-
Rozzano, Lombardy, Италия, 20089
- Рекрутинг
- Irccs Humanitas Research Hospital
-
-
-
-
Alberta
-
Edmonton, Alberta, Канада, T6G 2B7
- Рекрутинг
- University of Alberta Hospital
-
-
Ontario
-
Hamilton, Ontario, Канада, L8N 3Z5
- Рекрутинг
- McMaster University Medical Centre - Hamilton Health Sciences
-
-
Quebec
-
Montreal, Quebec, Канада, H4J 3A1
- Рекрутинг
- McGill University Health Center (MUHC)
-
-
-
-
-
Cambridge, Соединенное Королевство, CB2 0QQ
- Рекрутинг
- Addenbrooke's Hospital, Cambridge University Hospitals NHS FT
-
London, Соединенное Королевство, NW3 2QG
- Рекрутинг
- Royal Free London NHS Foundation Trust
-
London, Соединенное Королевство, SE1 7EH
- Рекрутинг
- St. Thomas' Hospital
-
London, Соединенное Королевство, W12 0HS
- Рекрутинг
- Hammersmith Hospital Comprehensive Care Centre
-
London, Соединенное Королевство, E1 2ES
- Рекрутинг
- Pathology and Pharmacy Building, The Royal London Hospital
-
-
Oxfordshire
-
Oxford, Oxfordshire, Соединенное Королевство, OX3 7HE
- Рекрутинг
- Oxford Haemophilia and Thrombosis Centre (OHTC)
-
-
Scotland
-
Glasgow, Scotland, Соединенное Королевство, G31 2ER
- Рекрутинг
- Glasgow Royal Infirmary - Clinical Research Facility
-
-
West Midlands
-
Birmingham, West Midlands, Соединенное Королевство, B15 2TH
- Рекрутинг
- Queen Elizabeth Hospital Birmingham
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85016
- Рекрутинг
- Phoenix Children's Hospital
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90027
- Рекрутинг
- Children's Hospital Los Angeles
-
Los Angeles, California, Соединенные Штаты, 90024
- Рекрутинг
- David Geffen School of Medicine at UCLA
-
Los Angeles, California, Соединенные Штаты, 90007
- Рекрутинг
- Orthopaedic Hemophilia Treatment Center
-
Sacramento, California, Соединенные Штаты, 95817
- Рекрутинг
- University of California Davis
-
San Francisco, California, Соединенные Штаты, 94143
- Рекрутинг
- University California San Francisco
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Рекрутинг
- University of Colorado Hemophilia and Thrombosis Center
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06510
- Рекрутинг
- Yale HTC
-
-
Florida
-
Gainesville, Florida, Соединенные Штаты, 32610
- Рекрутинг
- University of Florida
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46260
- Рекрутинг
- Indiana Hemophilia and Thrombosis Center
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Рекрутинг
- Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- Рекрутинг
- University of Michigan
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43205
- Рекрутинг
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Рекрутинг
- Children's Hospital of Philadelphia (CHOP)
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
- Рекрутинг
- Hemophilia Center of Western Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Рекрутинг
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75235
- Рекрутинг
- Children's Medical Center Dallas
-
Houston, Texas, Соединенные Штаты, 77030
- Рекрутинг
- University of Texas Health Science Center at Houston
-
-
-
-
Lyon
-
Bron, Lyon, Франция, 69677
- Рекрутинг
- Hospices Civils de Lyon
-
-
Nord
-
Lille, Nord, Франция, 59037
- Рекрутинг
- Hemostase Clinique, Institut Coeur Poumon
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Франция, 75015
- Рекрутинг
- Hopital Necker
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- Confirmed diagnosis of severe or moderately severe hemophilia B with medical history of FIX functional activity (≤2% or <0.02 IU/mL) or documented genotype known to produce severe hemophilia B
- Currently taking FIX prophylaxis and previous experience with FIX therapy, as defined in the protocol
- Participation in the lead-in period of this interventional study OR a separate lead-in study (R0000-HEMB-2187 [NCT05568459]) for at least 6 months for ABR data while taking FIX prophylaxis, as defined in the protocol
Key Exclusion Criteria:
- History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or more occasions
- Bethesda inhibitor titer greater than the Upper Limit of Normal (ULN) at screening
- Detectable pre-existing antibodies to the AAV8 capsid; as measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) at prescreening (or final lead-in visit, if applicable)
- Any significant underlying liver disease such as: cholestatic liver disease, liver cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy
- Evidence of advanced liver fibrosis or significant fatty liver, as defined in the protocol
- Evidence of cirrhosis and/or portal hypertension as assessed by abdominal ultrasound at screening or measured within 6 months prior to the screening visit
- History of arterial or venous thrombo-embolic events, as defined in the protocol
- History of hypersensitivity to corticosteroids or known medical condition that requires chronic administration of corticosteroids
- Previously received any AAV gene-based therapy or intends to receive approved or investigational AAV-based gene therapy other than REGV131-LNP1265 during the study period
NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part 1: Cohort 1 Dose Escalation for RDE
Starting dose to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 1: Cohort 2 Dose Escalation for RDE
Dose 2 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 1: Cohort 3 Dose Escalation for RDE
Dose 3 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 1: Cohort 4 Dose Escalation for RDE
Dose 4 of ascending dose level cohorts to determine the RDE of REGV131-LNP1265 and further assess the safety, tolerability, and FIX functional activity data at the RDE |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 2: Dose Expansion A
Participants ≥18 Years of Age will receive the RDE of REGV131-LNP1265 determined by Part 1 |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 2: Dose Expansion B
Participants ≥12 to <18 Years of Age will receive the administered weight-adjusted RDE of REGV131-LNP1265 determined by Part 1 |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
|
Экспериментальный: Part 2: Dose Expansion C
Participants ≥2 to <12 Years of Age will receive the administered weight-adjusted RDE of REGV131-LNP1265 determined by Part 1 |
Administered per the protocol before LNP1265 Administered per the protocol following REGV131 |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Временное ограничение: Up to 2 Years
|
Part 1, 2B, and 2C |
Up to 2 Years
|
|
Severity of TEAEs
Временное ограничение: Up to 2 Years
|
Part 1, 2B, and 2C |
Up to 2 Years
|
|
Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assay
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Change in FIX functional activity in plasma, measured using the chromogenic substrate assay
Временное ограничение: Up to 2 Years
|
Part 2A, 2B, and 2C |
Up to 2 Years
|
|
Annualized Bleeding Rate (ABR) following sustained FIX functional activity among participants receiving the RDE
Временное ограничение: Up to 2 Years
|
Part 2A, 2B, and 2C |
Up to 2 Years
|
|
Occurrence of Serious Adverse Events (SAEs)
Временное ограничение: Through Long Term Follow Up (LTFU), Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through Long Term Follow Up (LTFU), Up to 15 Years
|
|
Severity of SAEs
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Occurrence of Adverse Event of Special Interests (AESIs)
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Severity of AESIs
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Occurrence of clinically meaningful Adverse Events (AEs)
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Severity of clinically meaningful AEs
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in FIX functional activity in plasma measured using the chromogenic substrate assay
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
ABR following sustained FIX functional activity among participants receiving the RDE
Временное ограничение: Through LTFU, Up to 15 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
FIX functional activity in plasma over time during the study period using the chromogenic substrate assay
Временное ограничение: Through LTFU, Up to 10 Years
|
LTFU Period for Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 10 Years
|
|
Annualized treated Bleeding Rate (tABR) following sustained FIX functional activity, among participants receiving the RDE
Временное ограничение: Through LTFU, Up to 15 years
|
Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 years
|
|
Annualized utilization (IU/kg/year) of FIX replacement therapy following sustained FIX functional activity among participants receiving the RDE
Временное ограничение: Through LTFU, Up to 15 Years
|
Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Remaining free of FIX replacement therapy among those receiving the RDE following sustained FIX expression
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Remaining zero spontaneous bleeding events among those receiving the RDE over sustained FIX functional activity period
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Concentrations of REGV131 components
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Concentrations of LNP1265 components
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of antibodies to the Coagulation Factor IX gene (F9) transgene product FIX protein
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of Total binding Antibodies (TAbs) to the Adeno-Associated Virus 8 (AAV8) capsid proteins
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of Neutralizing Antibodies/Transduction Inhibitors (NAb/TI) to the AAV8 capsid proteins
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of antibodies to LNP1265
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of antibodies to CRISPR-associated protein 9 (Cas9) protein
Временное ограничение: Up to 2 Years
|
Part 1, 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of vector DeoxyriboNucleic Acid (DNA) in blood
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Detection of vector DNA in saliva
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Detection of vector DNA in nasal secretions
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Detection of vector DNA in semen
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Detection of vector DNA in urine
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Detection of vector DNA in feces
Временное ограничение: Up to 2 Years
|
Part 1 |
Up to 2 Years
|
|
Occurrence of TEAEs
Временное ограничение: Up to 2 Years
|
Part 2A |
Up to 2 Years
|
|
Severity of TEAEs
Временное ограничение: Up to 2 Years
|
Part 2A |
Up to 2 Years
|
|
Detection of vector DNA in relevant matrices based on data analysis of Part 1 Dose Confirmation Cohort
Временное ограничение: Up to 2 Years
|
Part 2A, 2B, and 2C |
Up to 2 Years
|
|
Detection of vector DNA in relevant matrices over time based on data analysis from adult cohorts over time
Временное ограничение: Up to 2 Years
|
Part 2B and 2C |
Up to 2 Years
|
|
Proportion of participants with zero spontaneous bleeding events following sustained FIX functional activity among those receiving RDE
Временное ограничение: Through LTFU, Up to 15 Years
|
Part 1, 2A, 2B, and 2C |
Through LTFU, Up to 15 Years
|
|
Proportion of participants not requiring FIX replacement therapy following sustained FIX functional activity among those receiving RDE
Временное ограничение: Throught LTFU, Up to 15 Years
|
Part 1, 2A, 2B, and 2C |
Throught LTFU, Up to 15 Years
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Clinical Trial Management, Regeneron Pharmaceuticals
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Генетические заболевания, врожденные
- Гематологические заболевания
- Нарушения свертывания крови
- Геморрагические расстройства
- Генетические заболевания, сцепленные с Х-хромосомой
- Нарушения свертывания крови, наследственные
- Нарушения белковой коагуляции
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Гемики и лимфатические заболевания
- Гемофилия В
Другие идентификационные номера исследования
- R131L1265-HEMB-2318
- 2023-507260-40-00 (Ктис)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Сроки обмена IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Критерии совместного доступа к IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- АНАЛИТИЧЕСКИЙ_КОД
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .